Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6906)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 18, 2015 (publication date) through May 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Maida M, Iavarone M, Raineri M, Cammà C, Cabibbo G. Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World J Hepatol 2015; 7(17): 2053-2057 [PMID: 26301047 DOI: 10.4254/wjh.v7.i17.2053] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i17/2053.htm |
| Number | Citing Articles |
| 1 |
David J. Pinato, Matthew W. Brown, Sebastian Trousil, Eric O. Aboagye, Jamie Beaumont, Hua Zhang, Helen M. Coley, Francesco A. Mauri, Rohini Sharma. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. British Journal of Cancer 2019; 120(5): 512 doi: 10.1038/s41416-018-0373-6
|
| 2 |
Alessandra Mazzola, Andrea Costantino, Salvatore Petta, Tommaso Vincenzo Bartolotta, Maurizio Raineri, Rodolfo Sacco, Giuseppe Brancatelli, Calogero Cammà, Giuseppe Cabibbo. Recurrence of hepatocellular carcinoma after liver transplantation: an update. Future Oncology 2015; 11(21): 2923 doi: 10.2217/fon.15.239
|
| 3 |
Giuseppe Cabibbo, Maria Reig, Gennaro Gadaleta-Caldarola, Giovanni Galati, Giuseppe Lombardi, GianCarlo Mazza, Luca Marzi, Carlo Saitta, Jean-Charles Nault, Rodolfo Sacco. The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 2. Future Oncology 2016; 12(3): 285 doi: 10.2217/fon.15.324
|
| 4 |
Giuseppe Cabibbo, Salvatore Petta, Marcello Maida, Calogero Cammà. Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. Digestive Diseases 2015; 33(5): 668 doi: 10.1159/000438477
|
| 5 |
David J. Pinato. Breaking Kuhn's paradigm in advanced hepatocellular carcinoma. Hepatology 2018; 67(5): 1663 doi: 10.1002/hep.29714
|
| 6 |
Michael J. Flynn, Anwar A. Sayed, Rohini Sharma, Abdul Siddique, David J. Pinato. Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Hepatology 2019; 69(5): 2258 doi: 10.1002/hep.30337
|
| 7 |
Rodolfo Sacco, Alessandro Granito, Irene Bargellini, Teresa Zolfino, Carlo Saitta, Luca Marzi, Gherardo Tapete, Giampaolo Bresci, Sara Marinelli, Francesco Tovoli, Simona Attardo, Margherita Rossi, Lucio Urbani, Santino Marchi, Piero Buccianti, Giuseppe Cabibbo. Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. Future Oncology 2018; 14(29): 3049 doi: 10.2217/fon-2018-0281
|
| 8 |
D. J. Pinato, C. Yen, D. Bettinger, R. Ramaswami, T. Arizumi, C. Ward, M. Pirisi, M. E. Burlone, R. Thimme, M. Kudo, R. Sharma. The albumin–bilirubin grade improves hepatic reserve estimation post‐sorafenib failure: implications for drug development. Alimentary Pharmacology & Therapeutics 2017; 45(5): 714 doi: 10.1111/apt.13904
|
| 9 |
David J. Pinato. Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinoma. Oncogene 2018; 37(34): 4635 doi: 10.1038/s41388-018-0262-8
|
| 10 |
Catia Giovannini, Manuela Minguzzi, Filippo Genovese, Michele Baglioni, Alessandra Gualandi, Matteo Ravaioli, Maddalena Milazzo, Simona Tavolari, Luigi Bolondi, Laura Gramantieri. Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. Oncotarget 2016; 7(26): 39609 doi: 10.18632/oncotarget.9203
|